GSK Introduces New Prefilled Syringe Presentation for Recombinant Zoster Vaccine

GSK Introduces New Prefilled Syringe Presentation for Recombinant Zoster Vaccine GlaxoSmithKline (GSK) has introduced a new prefilled syringe presentation for its Recombinant Zoster Vaccine (RZV) in Canada. The new presentation simplifies the vaccine administration process for healthcare professionals and is expected to be available across Canada beginning in early 2027. GlaxoSmithKline (GSK) has introduced a new prefilled syringe presentation for its Recombinant Zoster Vaccine (RZV) in Canada. This new presentation simplifies the vaccine administration process for healthcare professionals by removing the need to reconstitute separate vials prior to administration. The prefilled syringe presentation is expected to be available across Canada beginning in early 2027 and is licensed for the prevention of shingles in adults 50 years of age or older, as well as those 18 years of age or older who are or will be at increased risk of shingles due to immunodeficiency or immunosuppression caused by known disease or therapy. Shingles is a painful disease that can have serious and long-lasting complications, often imposing a greater burden on people living with common chronic diseases such as cardiovascular disease and diabetes.The new presentation is designed to improve ease of administration, delivering a practical solution to help healthcare professionals provide protection against shingles. Most adults will have the VZV dormant in their nervous system, which may reactivate with advancing age. As people age, the strength of the immune system response to infection decreases, increasing the risk of developing shingles.In addition to advancing age, chronic conditions like cardiovascular disease, chronic kidney disease, chronic obstructive pulmonary disease, asthma, and diabetes are all linked to higher risk of shingles. Following the rash, a person can also experience post-herpetic neuralgia (PHN), nerve pain that can last weeks or months and can occasionally persist for several years. The RZV vaccine is not indicated to prevent primary varicella infection (chickenpox) and should be used in accordance with official recommendations and local product label.The use of RZV may help overcome the natural age-related decline in responses to immunization that contributes to the challenge of protecting adults aged 50 and over from shingles, as well as those 18 years of age or older who are or will be at increased risk of shingles due to immunodeficiency or immunosuppression caused by known disease or therapy. GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.The company cautions investors that any forward-looking statements or projections made by GSK are subject to risks and uncertainties that may cause actual results to differ materially from those projected. The approval of the new prefilled syringe presentation is based on data confirming technical comparability between the new and existing vaccine presentations. The RZV vaccine consists of two vials, a lyophilized (powder) antigen and a liquid adjuvant, which healthcare professionals combine prior to administering.The prefilled syringe presentation provides a convenient method of administration, eliminating the need for reconstitution of separate vials. This new presentation is expected to be available across Canada in early 2027, providing a practical solution to help healthcare professionals provide protection against shingles. GSK's new prefilled syringe presentation for RZV is a significant development in the fight against shingles, offering a convenient and practical solution for healthcare professionals to administer the vaccine.The new presentation is expected to be widely available in Canada, providing access to the RZV vaccine for those at risk of shingles. The RZV vaccine is not indicated to prevent primary varicella infection (chickenpox) and should be used in accordance with official recommendations and local product label.The use of RZV may help overcome the natural age-related decline in responses to immunization that contributes to the challenge of protecting adults aged 50 and over from shingles, as well as those 18 years of age or older who are or will be at increased risk of shingles due to immunodeficiency or immunosuppression caused by known disease or therapy